The Latest Breaking News from Obesity

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise

Analysis: It’s been heralded as the ‘fountain of youth’ that could cure heart problems and promote rapid weight loss, but could Ozempic change all our lives, asks Rebecca Thomas

The study suggests that obesity not only worsens the outcomes of COVID but also increases the risk for infection upon exposure.

The company claims the Zepbound doses cost 50% less than competing drugs

Consumers in the US put their trust in organizations such as the Food and Drug Administration to keep foods, fish, and livestock safe - but to what standards?

Researchers say the findings back the recommendations to reduce meat intake

Participants of a survey conducted by Ipsos said the taxes would help combat the country’s obesity crisis